Interim financial report for 1 January - 30 September 2023 for FirstFarms A/S
FirstFarms delivers satisfactory in challenging market
FirstFarms generates reasonable results despite high inflation on costs and great pressure on sales prices. Turnover increase of 19% and announced expectations for the year are maintained.
The Board of Directors and Management of FirstFarms A/S have today reviewed and adopted the unaudited interim financial accounts for the period 1 January – 30 September 2023.
FirstFarms has in the accounting period realised:
- Net turnover: 345 mDKK (2022: 291 mDKK)
- EBITDA: 79 mDKK (2022: 121 mDKK)
- EBIT: 42 mDKK (2022: 89 mDKK)
- Pre-tax result: 28 mDKK (2022: 77 mDKK)
Production and result generation are satisfactory based on the challenging conditions FirstFarms has operated under during the first three quarters of the year. The result is achieved as a result of a stable, efficient, circular operation and the risk diversification, which is an important and positive characteristic of the Group.
Thus, FirstFarms A/S maintains the announced expectations for 2023. However, with an EBITDA in the lower end of the level of 90-120 mDKK and an EBIT correspondingly in the lower end of the level of 45-75 mDKK.
CEO Anders H. Nørgaard says:
"We are happy to be able to maintain the expectations for the year's result, even though we are in the lower part of the range. Our efficiency and production are stable and when one branch of operation fails as a result of low sales prices or as a result of regional weather conditions, we skillfully compensate in branches of operation. As predicted, 2023 has been a difficult year to operate in and compared to recent record years, 2023 may also appear as a bad year - that's not how we experience it. We are on the contrary happy and proud that we can create the results we do under such difficult conditions.”
The prices have stabilised
The general cost level has been higher in the period compared to the same period last year, and as expected the higher prices of pigs and crops began to decrease in the first half of the year. However, the price decrease has been larger than expected but has now stabilised. For the pigs at an acceptable level. For the crops at too low a level. However, the crops from 2023 have been sold at higher prices than the current market prices. The milk prices are at a reasonably high level.
In addition to the stable operations, added value on agricultural land and buildings provides protection against inflation. There are net over 200 mDKK off-the-books reserves on the land, which can be added to the value of FirstFarms.
Growth in the pig production
The Group's two new pig production facilities in Hungary are in full production with a capacity for 2,000 sows and piglets. The first piglets will be delivered in Q4, 2023. The start-up costs for 2023 amount to 10 mDKK, which affects the year's result negatively.
Milk price is stable
In the first three quarters, milk production has been at the same level as the same period in 2022. The milk price has stabilised at a reasonably high level (DKK 3.16/kg) and has year to date been DKK 3.56/kg on average against 3.23 DKK/kg in 2022. In total, this has resulted in a turnover from milk production of 91 mDKK in 2023 against 83 mDKK in 2022.
Decreasing crop prices are not fully reflected
The input costs of crop production have increased, and the price of crops has dropped more than expected compared to 2022, which saw historically high crop prices. However, it has been possible to sell crops at prices that are higher than the current market price, and therefore the current market prices do not fully reflect on the outcome.
For further information:
Please visit our website www.firstfarms.com or contact CEO Anders H. Nørgaard on phone +45 75 86 87 87.
FirstFarms is a Danish stock exchange listed company. We operate FirstFarms with responsibility for the surrounding communities, and we deliver highest quality which is primarily sold locally. We act on new opportunities, that create value for our investors and for the surroundings. Every day, we work on creating a more sustainable company.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria24.2.2024 15:51:43 CET | Press release
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSUData form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024Pivotal Phase 3 readout in immune thrombocytopenia and Phase 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia expected in 2024Rilzabrutinib is one of 12 potential blockbusters in Sanofi’s leading immunology pipeline Paris, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These r
Application to delist from Nasdaq First North Growth Market Denmark submitted24.2.2024 14:17:57 CET | Press release
Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of the delisting procedure and consequenses for shareholders is stated in the company announcement 01-2024. ---- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. a
798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release
BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release
Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,